Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
1.92B
Market cap1.92B
Price-Earnings ratio
-4.51
Price-Earnings ratio-4.51
Dividend yield
Dividend yield
Average volume
14.59M
Average volume14.59M
High today
$4.48
High today$4.48
Low today
$4.20
Low today$4.20
Open price
$4.32
Open price$4.32
Volume
10.34M
Volume10.34M
52 Week high
$5.63
52 Week high$5.63
52 Week low
$1.70
52 Week low$1.70

Stock Snapshot

As of today, Iovance Biotherapeutics(IOVA) shares are valued at $4.32. The company's market cap stands at 1.92B, with a P/E ratio of -4.51.

During the trading session on 2026-07-09, Iovance Biotherapeutics(IOVA) shares reached a daily high of $4.48 and a low of $4.20. At a current price of $4.32, the stock is +3.0% higher than the low and still -3.6% under the high.

Trading activity shows a volume of 10.34M, compared to an average daily volume of 14.59M.

Over the past 52 weeks, Iovance Biotherapeutics(IOVA) stock has traded between a high of $5.63 and a low of $1.70.

Over the past 52 weeks, Iovance Biotherapeutics(IOVA) stock has traded between a high of $5.63 and a low of $1.70.

IOVA News

The Motley Fool 7h
This Stock Is Up 74% This Year: Is It Too Late to Buy?

After several years of underperforming the market, Iovance Biotherapeutics (IOVA 1.61%) is finally bouncing back. The biotech company's shares have soared 74% t...

This Stock Is Up 74% This Year: Is It Too Late to Buy?
Simply Wall St 5d
Does Reaffirmed 2026 Revenue Guidance And Cash Runway To 2028 Change The Bull Case For Iovance? - simplywall.st

...

Does Reaffirmed 2026 Revenue Guidance And Cash Runway To 2028 Change The Bull Case For Iovance? - simplywall.st
TipRanks 6d
Iovance updates outlook, highlighting Amtagvi growth and pipeline

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.